Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide

Journal of Virology

Volumn 88, Issue 16, 2014, Pages 9406-9417

  Dennison, S Moses ^a   Anasti, Kara M ^a   Jaeger, Frederick H ^a   Stewart, Shelley M ^a   Pollara, Justin ^a   Liu, Pinghuang ^a   Kunz, Erika L ^a   Zhang, Ruijun ^a   Vandergrift, Nathan ^a   Permar, Sallie ^a   Ferrari, Guido ^a   Tomaras, Georgia D ^a   Bonsignori, Mattia ^a   Michael, Nelson L ^b   Kim, Jerome H ^b   Kaewkungwal, Jaranit ^c   Nitayaphan, Sorachai ^d   Pitisuttithum, Punnee ^c   Rerks Ngarm, Supachai ^e   Liao, Hua Xin ^a   Haynes, Barton F ^a   Alam, S Munir ^a   more..

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

^d ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^e MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALVAC; CD4 ANTIGEN; EPITOPE; GALACTOSYLCERAMIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LIPOSOME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 17B; PALIVIZUMAB; UNCLASSIFIED DRUG;

ANTIBODY COMBINING SITE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ARTICLE; CONFORMATIONAL TRANSITION; DISSOCIATION CONSTANT; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; UPREGULATION;

AIDS VACCINES; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD4; BINDING SITES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; GALACTOSYLCERAMIDES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNOGLOBULIN G; LIPOSOMES; PROTEIN BINDING;

EID: 84904878889     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01031-14     Document Type: Article

References (66)

1. Haynes BF, Shattock RJ. 2008. Critical issues in mucosal immunity for HIV-1 vaccine development. J. Allergy Clin. Immunol. 122:3-9. http://dx.doi.org/10.1016/j.jaci.2008.03.036.
2. Hope TJ. 2011. Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question. Nat. Med. 17:1195-1197. http://dx.doi.org/10.1038/nm.2528.
3. McElrath MJ, Haynes BF. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33:542-554. http://dx.doi.org/10.1016/j.immuni.2010.09.011.
4. Carias AM, McCoombe S, McRaven M, Anderson M, Galloway N, Vandergrift N, Fought AJ, Lurain J, Duplantis M, Veazey RS, Hope TJ. 2013. Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract. J. Virol. 87:11388-11400. http://dx.doi.org/10.1128/JVI.01377-13.
5. Shukair SA, Allen SA, Cianci GC, Stieh DJ, Anderson MR, Baig SM, Gioia CJ, Spongberg EJ, Kauffman SM, McRaven MD, Lakougna HY, Hammond C, Kiser PF, Hope TJ. 2013. Human cervicovaginal mucus contains an activity that hinders HIV-1 movement. Mucosal Immunol. 6:427-434. http://dx.doi.org/10.1038/mi.2012.87.
6. Hladik F, McElrath MJ. 2008. Setting the stage: host invasion by HIV. Nat. Rev. Immunol. 8:447-457. http://dx.doi.org/10.1038/nri2302.
7. Bhat S, Spitalnik SL, Gonzalez-Scarano F, Silberberg DH. 1991. Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120. Proc. Natl. Acad. Sci. U. S. A. 88:7131-7134. http://dx.doi.org/10.1073/pnas.88.16.7131.
8. Harouse JM, Bhat S, Spitalnik SL, Laughlin M, Stefano K, Silberberg DH, Gonzalez-Scarano F. 1991. Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science 253:320-323. http://dx.doi.org/10.1126/science.1857969.
9. Harouse JM, Kunsch C, Hartle HT, Laughlin MA, Hoxie JA, Wigdahl B, Gonzalez-Scarano F. 1989. CD4-independent infection of human neural cells by human immunodeficiency virus type 1. J. Virol. 63:2527-2533.
10. Yahi N, Baghdiguian S, Moreau H, Fantini J. 1992. Galactosyl ceramide (or a closely related molecule) is the receptor for human immunodeficiency virus type 1 on human colon epithelial HT29 cells. J. Virol. 66: 4848-4854.
11. Chen P, Hubner W, Spinelli MA, Chen BK. 2007. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J. Virol. 81:12582-12595. http://dx.doi.org/10.1128/JVI.00381-07.
12. Dale BM, Alvarez RA, Chen BK. 2013. Mechanisms of enhanced HIV spread through T-cell virological synapses. Immunol. Rev. 251:113-124. http://dx.doi.org/10.1111/imr.12022.
13. Holgersson J, Jovall PA, Breimer ME. 1991. Glycosphingolipids of human large intestine: detailed structural characterization with special reference to blood group compounds and bacterial receptor structures. J. Biochem. 110:120-131.
14. Raff MC, Mirsky R, Fields KL, Lisak RP, Dorfman SH, Silberberg DH, Gregson NA, Leibowitz S, Kennedy MC. 1978. Galactocerebroside is a specific cell-surface antigenic marker for oligodendrocytes in culture. Nature 274:813-816.
15. Simons K, van Meer G. 1988. Lipid sorting in epithelial cells. Biochemistry 27:6197-6202. http://dx.doi.org/10.1021/bi00417a001.
16. Bobardt MD, Chatterji U, Selvarajah S, Van der Schueren B, David G, Kahn B, Gallay PA. 2007. Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J. Virol. 81:395-405. http://dx.doi.org/10.1128/JVI.01303-06.
17. Yeaman GR, Asin S, Weldon S, Demian DJ, Collins JE, Gonzalez JL, Wira CR, Fanger MW, Howell AL. 2004. Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type I. Immunology 113:524-533. http://dx.doi.org/10.1111/j.1365-2567.2004.01990.x.
18. Dorosko SM, Connor RI. 2010. Primary human mammary epithelial cells endocytose HIV-1 and facilitate viral infection of CD4+ T lymphocytes. J. Virol. 84:10533-10542. http://dx.doi.org/10.1128/JVI.01263-10.
19. Fantini J, Cook DG, Nathanson N, Spitalnik SL, Gonzalez-Scarano F. 1993. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc. Natl. Acad. Sci. U. S. A. 90:2700-2704. http://dx.doi.org/10.1073/pnas.90.7.2700.
20. Conboy JC, McReynolds KD, Gervay-Hague J, Saavedra SS. 2000. gp120 binds cooperatively to several biologically relevant glycosphingolipids: quantitative measurements at equilibrium by total internal reflection fluorescence microscopy. Angew. Chem. Int. Ed. Engl. 39:2882-2884. http://dx.doi.org/10.1002/1521-3773(20000818)39:162882::AID-ANIE28823.0.CO;2-M.
21. Conboy JC, McReynolds KD, Gervay-Hague J, Saavedra SS. 2002. Quantitative measurements of recombinant HIV surface glycoprotein 120 binding to several glycosphingolipids expressed in planar supported lipid bilayers. J. Am. Chem. Soc. 124:968-977. http://dx.doi.org/10.1021/ja011225s.
22. Long D, Berson JF, Cook DG, Doms RW. 1994. Characterization of human immunodeficiency virus type 1 gp120 binding to liposomes containing galactosylceramide. J. Virol. 68:5890-5898.
23. McAlarney T, Apostolski S, Lederman S, Latov N. 1994. Characteristics of HIV-1 gp120 glycoprotein binding to glycolipids. J. Neurosci. Res. 37: 453-460. http://dx.doi.org/10.1002/jnr.490370404.
24. Nehete PN, Vela EM, Hossain MM, Sarkar AK, Yahi N, Fantini J, Sastry KJ. 2002. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains. Antiviral Res. 56:233-251. http://dx.doi.org/10.1016/S0166-3542(02)00130-4.
25. Schust DJ, Ibana JA, Buckner LR, Ficarra M, Sugimoto J, Amedee AM, Quayle AJ. 2012. Potential mechanisms for increased HIV-1 transmission across the endocervical epithelium during C. trachomatis infection. Curr. HIV Res. 10:218-227. http://dx.doi.org/10.2174/157016212800618093.
26. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893. http://dx.doi.org/10.1016/S0140-6736(08) 61591-3.
27. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN. 2012. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J. Infect. Dis. 206:258-266. http://dx.doi.org/10.1093/infdis/jis342.
28. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191:654-665. http://dx.doi.org/10.1086/428404.
29. Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V, Hu DJ, Heyward WL, Sinangil F, Shepherd BE, Gurwith M. 2005. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J. Infect. Dis. 192:974-983. http://dx.doi.org/10.1086/432734.
30. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG. 2011. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect. Dis. 11:507-515. http://dx.doi.org/10.1016/S1473-3099(11)70098-6.
31. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, Dejesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB. 2013. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 369:2083-2092. http://dx.doi.org/10.1056/NEJMoa1310566.
32. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:1894-1905. http://dx.doi.org/10.1016/S0140-6736(08)61592-5.
33. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-1671. http://dx.doi.org/10.1086/508748.
34. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220. http://dx.doi.org/10.1056/NEJMoa0908492.
35. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286. http://dx.doi.org/10.1056/NEJMoa1113425.
36. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, DeVico A, Evans DT, Ferrari G, Liao HX, Haynes BF. 2012. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86:11521-11532. http://dx.doi.org/10.1128/JVI.01023-12.
37. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, Poling B, Nicholson CO, Zhang R, Lu X, Parks R, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Gilbert PB, Kim JH, Michael NL, Montefiori DC, Haynes BF. 2013. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl. Acad. Sci. U. S. A. 110:9019-9024. http://dx.doi.org/10.1073/pnas.1301456110.
38. Liu P, Yates NL, Shen X, Bonsignori M, Moody MA, Liao HX, Fong Y, Alam SM, Overman RG, Denny T, Ferrari G, Ochsenbauer C, Kappes JC, Polonis VR, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Montefiori DC, Gilbert P, Michael NL, Kim JH, Haynes BF, Tomaras GD. 2013. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J. Virol. 87:7828-7836. http://dx.doi.org/10.1128/JVI.02737-12.
39. Cook DG, Fantini J, Spitalnik SL, Gonzalez-Scarano F. 1994. Binding of human immunodeficiency virus type I (HIV-1) gp120 to galactosylceramide (GalCer): relationship to the V3 loop. Virology 201:206-214. http://dx.doi.org/10.1006/viro.1994.1287.
40. Alfsen A, Iniguez P, Bouguyon E, Bomsel M. 2001. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J. Immunol. 166:6257-6265. http://dx.doi.org/10.4049/jimmunol.166.10.6257.
41. Yu H, Alfsen A, Tudor D, Bomsel M. 2008. The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent. Cell Calcium 43:73-82. http://dx.doi.org/10.1016/j.ceca.2007.04.011.
42. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP. 2011. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. U. S. A. 108:11181-11186. http://dx.doi.org/10.1073/pnas.1103012108.
43. Liao HX, Tsao CY, Alam SM, Muldoon M, Vandergrift N, Ma BJ, Lu X, Sutherland LL, Scearce RM, Bowman C, Parks R, Chen H, Blinn JH, Lapedes A, Watson S, Xia SM, Foulger A, Hahn BH, Shaw GM, Swanstrom R, Montefiori DC, Gao F, Haynes BF, Korber B. 2013. Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J. Virol. 87:4185-4201. http://dx.doi.org/10.1128/JVI.02297-12.
44. Ranscht B, Clapshaw PA, Price J, Noble M, Seifert W. 1982. Development of oligodendrocytes and Schwann cells studied with a monoclonal antibody against galactocerebroside. Proc. Natl. Acad. Sci. U. S. A. 79: 2709-2713. http://dx.doi.org/10.1073/pnas.79.8.2709.
45. Alam SM, Scearce RM, Parks RJ, Plonk K, Plonk SG, Sutherland LL, Gorny MK, Zolla-Pazner S, Vanleeuwen S, Moody MA, Xia SM, Montefiori DC, Tomaras GD, Weinhold KJ, Karim SA, Hicks CB, Liao HX, Robinson J, Shaw GM, Haynes BF. 2008. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 82:115-125. http://dx.doi.org/10.1128/JVI.00927-07.
46. Nicely NI, Dennison SM, Spicer L, Scearce RM, Kelsoe G, Ueda Y, Chen H, Liao HX, Alam SM, Haynes BF. 2010. Crystal structure of a nonneutralizing antibody to the HIV-1 gp41 membrane-proximal external region. Nat. Struct. Mol. Biol. 17:1492-1494. http://dx.doi.org/10.1038/nsmb.1944.
47. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1215-1224. http://dx.doi.org/10.1086/514115.
48. Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, Dormitzer PR, Haynes BF, Walter EB, Moody MA, Kepler TB, Liao HX, Harrison SC. 2011. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl. Acad. Sci. U. S. A. 108:14216-14221. http://dx.doi.org/10.1073/pnas.1111497108.
49. Edmonds TG, Ding H, Yuan X, Wei Q, Smith KS, Conway JA, Wieczorek L, Brown B, Polonis V, West JT, Montefiori DC, Kappes JC, Ochsenbauer C. 2010. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408:1-13. http://dx.doi.org/10.1016/j.virol.2010.08.028.
50. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, Kappes JC, Shaw GM, Hoxie JA, Robinson JE, Haynes BF. 2011. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a commonADCCepitope in human HIV-1 serum. J. Virol. 85:7029-7036. http://dx.doi.org/10.1128/JVI.00171-11.
51. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, Liu P, Lu X, Parks RJ, Montefiori DC, Ferrari G, Pollara J, Rao M, Peachman KK, Santra S, Letvin NL, Karasavvas N, Yang ZY, Dai K, Pancera M, Gorman J, Wiehe K, Nicely NI, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Sinangil F, Kim JH, Michael NL, Kepler TB, Kwong PD, Mascola JR, Nabel GJ, Pinter A, Zolla-Pazner S, Haynes BF. 2013. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38:176-186. http://dx.doi.org/10.1016/j.immuni.2012.11.011.
52. Moreno MR, Giudici M, Villalain J. 2006. The membranotropic regions of the endo and ecto domains of HIV gp41 envelope glycoprotein. Biochim. Biophys. Acta 1758:111-123. http://dx.doi.org/10.1016/j.bbamem.2006.01.007.
53. Moreno MR, Pascual R, Villalain J. 2004. Identification of membraneactive regions of the HIV-1 envelope glycoprotein gp41 using a 15-mer gp41-peptide scan. Biochim. Biophys. Acta 1661:97-105. http://dx.doi.org/10.1016/j.bbamem.2003.12.003.
54. + T cells as key targets in mucosal transmission. PLoS Pathog. 7:e1001301. http://dx.doi.org/10.1371/journal.ppat.1001301.
55. Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, Salazar-Gonzalez JF, Salazar MG, Decker JM, Parrish EH, Berg A, Hopper J, Hora B, Kumar A, Mahlokozera T, Yuan S, Coleman C, Vermeulen M, Ding H, Ochsenbauer C, Tilton JC, Permar SR, Kappes JC, Betts MR, Busch MP, Gao F, Montefiori D, Haynes BF, Shaw GM, Hahn BH, Doms RW. 2012. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog. 8:e1002686. http://dx.doi.org/10.1371/journal.ppat.1002686.
56. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, Zajic L, Iyer SS, Decker JM, Kumar A, Hora B, Berg A, Cai F, Hopper J, Denny TN, Ding H, Ochsenbauer C, Kappes JC, Galimidi RP, West AP, Jr, Bjorkman PJ, Wilen CB, Doms RW, O'Brien M, Bhardwaj N, Borrow P, Haynes BF, Muldoon M, Theiler JP, Korber B, Shaw GM, Hahn BH. 2013. Phenotypic properties of transmitted founder HIV-1. Proc. Natl. Acad. Sci. U. S. A. 110:6626-6633. http://dx.doi.org/10.1073/pnas.1304288110.
57. Moore JP, Sodroski J. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
58. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.
59. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659. http://dx.doi.org/10.1038/31405.
60. Garg H, Francella N, Tony KA, Augustine LA, Barchi JJ, Jr, Fantini J, Puri A, Mootoo DR, Blumenthal R. 2008. Glycoside analogs of betagalactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry. Antiviral Res. 80:54-61. http://dx.doi.org/10.1016/j.antiviral.2008.04.004.
61. Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, Hwang KK, Gurley TC, Kozink DM, Armand LC, Marshall DJ, Whitesides JF, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, O'Connell RJ, Kim JH, Michael NL, Montefiori DC, Tomaras GD, Liao HX, Haynes BF, Ferrari G. 2014. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J. Virol. 88:7715-7726. http://dx.doi.org/10.1128/JVI.00156-14.
62. Kaizu M, Weiler AM, Weisgrau KL, Vielhuber KA, May G, Piaskowski SM, Furlott J, Maness NJ, Friedrich TC, Loffredo JT, Usborne A, Rakasz EG. 2006. Repeated intravaginal inoculation with cell-associated simian immunodeficiency virus results in persistent infection of nonhuman primates. J. Infect. Dis. 194:912-916. http://dx.doi.org/10.1086/507308.
63. Salle B, Brochard P, Bourry O, Mannioui A, Andrieu T, Prevot S, Dejucq-Rainsford N, Dereuddre-Bosquet N, Le Grand R. 2010. Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J. Infect. Dis. 202:337-344. http://dx.doi.org/10.1086/653619.
64. Martin N, Welsch S, Jolly C, Briggs JA, Vaux D, Sattentau QJ. 2010. Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J. Virol. 84:3516-3527. http://dx.doi.org/10.1128/JVI.02651-09.
65. Bomsel M, Heyman M, Hocini H, Lagaye S, Belec L, Dupont C, Desgranges C. 1998. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 9:277-287. http://dx.doi.org/10.1016/S1074-7613(00) 80610-X.
66. Magerus-Chatinet A, Yu H, Garcia S, Ducloux E, Terris B, Bomsel M. 2007. Galactosyl ceramide expressed on dendritic cells can mediate HIV-1 transfer from monocyte derived dendritic cells to autologous T cells. Virology 362:67-74. http://dx.doi.org/10.1016/j.virol.2006.11.035.